Orchestra BioMed Holdings, Inc. OBIO

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001814114


None

No letter

6 of 13 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $114.9M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, short runway, thin data; fortr...
Inputs computable	6 of 13
Graded from	filings received through Mar 12, 2026 250 days before the rescan; latest periodic filing 10-Q received Nov 10, 2026
Last close	$7.10 2026-11-16; market equity $558.8M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 12, 2026

Our vision is to accelerate medical innovation to patients through risk-reward-sharing partnerships with leading medical device companies. We are a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. We are led by a highly accomplished, multidisciplinary management team and a board of directors with extensive experience in all phases of therapeutic device development. Our business was formed in 2018 by assembling a pipeline of multiple late-stage clinical product candidates originally developed by our founding team.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 59.1						
Gross profitability	29.0%	32.8%		51.9	346	2025-12-31
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(3.9%)	(6.7%)		66.4	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 3						
Solvency, sleeve percentile 43.6						
Altman Z double-prime	(7.02)	0.31		57.5	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(3.61x)				
one or more required annual facts are missing						
Current ratio	6.45x	2.68x		29.6	781	2025-12-31
Growth and financing, sleeve percentile 57.6						
Revenue growth, three-year compound	not computable	9.6%				
four annual observations are required; found 3						
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 3						
Reinvestment rate	not computable	33.9%				
one or more required annual facts are missing						
Asset growth, three years	6.3%	3.2%		38.2	663	2025-12-31
Net share issuance, one year	52.7%	1.6%		76.9	624	2026-03-10

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 52.7%
Short runway	cash runway is 5.3 months
Thin data	6 of 13 grade factors are computable; minimum is 7
Fortress balance sheet	cash minus debt is 19,690,000 USD; Altman Z is not used

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	59.5%	(1.7%)	83
Distance from 52-week high	(1.8%)	(31.5%)	92
EBIT to enterprise value	(9.5%)	0.5%	29
Free cash flow yield	(8.8%)	0.5%	29
Book value to price	0.01	0.28	12
Sales to price	0.06	0.36	12
Composite equity issuance, five years	134.8%	13.2%	87
Relative strength against the sector, log excess return	0.30	(0.19)	83
Twelve-month failure probability, CHS model	0.14%	0.06%	69

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$27.8M
Operating cash flow, four quarters	-$63.3M
Months of runway	5.3
Days since last periodic filing	7 (10-Q received Nov 10, 2026)
Median daily dollar volume, 63 sessions	$1.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	$33.5M	2025-12-31	2026-03-12	10-K	26-026754
2	cost of revenue	us-gaap:CostOfRevenue	$190,000	2025-12-31	2026-03-12	10-K	26-026754
3	assets	us-gaap:Assets	$114.9M	2025-12-31	2026-03-12	10-K	26-026754
4	net income	us-gaap:NetIncomeLoss	-$52.7M	2025-12-31	2026-03-12	10-K	26-026754
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$49.0M	2025-12-31	2026-03-12	10-K	26-026754
6	assets	us-gaap:Assets	$76.2M	2024-12-31	2026-03-12	10-K	26-026754
7	current assets	us-gaap:AssetsCurrent	$107.9M	2025-12-31	2026-03-12	10-K	26-026754
8	current liabilities	us-gaap:LiabilitiesCurrent	$16.7M	2025-12-31	2026-03-12	10-K	26-026754
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$362.6M	2025-12-31	2026-03-12	10-K	26-026754
10	operating income	us-gaap:OperatingIncomeLoss	-$51.8M	2025-12-31	2026-03-12	10-K	26-026754
11	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableT...	$53.6M	2025-12-31	2026-03-12	10-K	26-026754
12	liabilities	us-gaap:Liabilities	$51.5M	2025-12-31	2026-03-12	10-K	26-026754
13	total debt	us-gaap:LongTermDebt	$15.0M	2025-12-31	2026-03-12	10-K	26-026754
14	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$34.7M	2025-12-31	2026-03-12	10-K	26-026754
15	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$327,000	2025-12-31	2026-03-12	10-K	26-026754
16	revenue	us-gaap:Revenues	$2.6M	2024-12-31	2026-03-12	10-K	26-026754
17	revenue	us-gaap:Revenues	$2.8M	2023-12-31	2025-03-31	10-K	25-004161
18	assets	us-gaap:Assets	$95.2M	2023-12-31	2025-03-31	10-K	25-004161
19	assets	us-gaap:Assets	$95.6M	2022-12-31	2024-03-27	10-K	24-004083
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	58,520,901	2026-03-10	2026-03-12	10-K	26-026754
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	38,312,512	2025-03-27	2025-03-31	10-K	25-004161

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.